Immunohematology/Transfusion Medicine Research Training

提案摘要 本次T32更新计划继续保持其在免疫血液学博士后培训方面的良好记录 2001年开始的输血医学。该6个职位的计划提供了一个高度组织2-3年 专注的教学经验，研讨会，并与32个良好的一个激烈的研究经验- 来自九个不同小学的知名、高度互动和资金充足的跨学科导师 部门其目标是培养富有成效的MD和MD/PhD医生科学家以及博士 科学家和临床科学家，他们开始了终身的研究事业，追求基础， 翻译和临床研究在这个相对代表性不足的领域。我们建议扩大培训 计划包括2 MD/博士和博士预科生，谁也将受益于独特的培训 T32提供的机会。三个主要的学位授予“轨道”也可用于MD博士后： 一个调查医学博士学位提供给只希望获得更广泛研究的医学博士学员 背景模仿医学博士/博士;健康科学硕士的重点是T3-T4 研究;和生物医学工程硕士学位的学员与过去的生物医学重点谁希望 在他们的职业生涯中增加了诊断和细胞治疗工程的维度。主要来自一个 MD，MD/PhD和PhD候选人库，专注于实验室医学和病理学背景， 成人和儿童血液学和免疫学/ID程序的补充（始终包括 至少10倍以上的优秀，TG合格，候选人比被接受），结果是相当积极的。 在过去15年中，T32计划的36名毕业生中，平均有4.5篇论文和2篇第一， 作为T32培训的直接成果，每位学员发表的作者论文数。7个仍在培训中（例如，临床 奖学金，正在进行的研究与独立的K资金）。在其余29个国家中，96%（28个）属于科学领域。 职业; 41%（12）在研究型大学的终身制研究密集型职位; 21%（6）在职业 在主要大学的阶梯研究轨道上，34%（10人）在工业界担任高级科学家职务。作为 耶鲁大学唯一的良性血液学T32，少数几个免疫血液学/输血医学T32之一， 国家强调博士临床科学家（一个重要的替代职业途径博士）沿着 MD和MD/PhD医生科学家，也是为数不多的博士后血液学T32之一，包括 生物工程和博士学位的轨道MD-onlies，这个计划填补了一个重要的研究培训需求 无论是在耶鲁还是全国

PROPOSAL SUMMARY This T32 renewal proposes to continue its strong track record of postdoctoral training in Immunohematology and Transfusion Medicine initiated in 2001. The 6 position program provides a highly organized 2-3 year experience of focused dedicated didactics, seminars, and an intense research experience with one of 32 well- established, highly interactive, and well-funded cross-disciplinary mentors from nine different primary departments. The goal is to generate productive MD and MD/PhD physician-scientists as well as PhD scientists and clinician-scientists, who are launched on a lifelong investigative career pursuing basic, translational, and clinical research in this relatively underrepresented field. We propose to expand the training program to include 2 MD/PhD and PhD predoctoral students, who will also benefit from the unique training opportunities provided by this T32. Three major degree granting "tracks" are also available for MD post-docs: an Investigative Medicine PhD available to MD-only trainees who wish to obtain a more expansive research background mimicking that of an MD/PhD; a Master’s of Health Sciences for those with an emphasis on T3-T4 research; and a Masters of Biomedical Engineering for trainees with a past biomedicine emphasis who wish to add a diagnostic and cellular therapeutic engineering dimension to their career. Drawn predominantly from an MD, MD/PhD, and PhD candidate pool with a background focused on Laboratory Medicine & Pathology, with additions from adult and pediatric Hematology and Immunology/ID programs (a pool that has always included at least 10 fold more excellent, TG eligible, candidates than are accepted), outcomes have been quite positive. Of the 36 graduates of the T32 program over the past 15 years, there was an average of 4.5 papers and 2 first- author papers per trainee published as a direct result of the T32 training. Seven are still in training (e.g. clinical fellowship, ongoing research with independent K funding). Of the remaining 29, 96% (28) are in scientific careers; 41% (12) are in tenure-track research-intensive positions at research universities; 21% (6) in careers on the ladder research track at major universities, and 34% (10) are in senior scientist positions in industry.. As the only benign hematology T32 at Yale, one of the few Immunohematology/Transfusion Medicine T32s in the country that emphasizes PhD clinician-scientists (an important alternate career pathway for PhDs) along with MD and MD/PhD physician-scientists, and also one of the few postdoctoral hematology T32s that includes bioengineering and PhD degree tracks for MD-onlies, this program fills an important research training need both at Yale and nationally.